Neoplasm
Not yet recruitingA study to evaluate the safety and effectiveness of BMS-986523 alone or in combination with a drug combination for patients with advanced solid tumors and KRAS alterations.
A study to evaluate the safety and effectiveness of BMS-986523 alone or in combination with a drug combination for patients with advanced solid tumors and KRAS alterations.
- Disease:Neoplasm
- Substances:BMS-986523
Spain- Participants:18–64 years · 65+ years
- Substances:BMS-986523
- Sponsor:Bristol-Myers Squibb Services Unlimited Company










